Anti-11beta-Hydroxysteroid Dehydrogenase (Type 2)

11beta-Hydroxysteroid Dehydrogenase (Type 2) (11beta-HSD2) catalyzes the conversion of cortisol (hydrocortisone, Cay-20739) to the inactive glucocorticoid cortisone (Cay-30763), thereby protecting the mineralcorticoid receptor from glucocorticoid excess. It is primarily expressed in the kidneys, but has also been detected in the colon, salivary glands, and fetal tissues, including the placenta, and is localized to the endoplasmic reticulum. Knockout of HSD11B2, the gene encoding 11beta-HSD2, reduces fetal and placental growth as well as capillary development in mice. Loss-of-function mutations in HSD11B2 result in apparent mineralcorticoid excess (AME), an inborn error of metabolism characterized by hypertension, hypokalemia, and reduced plasma renin activity. Cayman's 11beta-Hydroxysteroid Dehydrogenase (Type 2) Polyclonal Antibody can be used for immunohistochemistry (IHC) and Western blot (WB) applications. The antibody recognizes 11beta-HSD2 at 44 kDa from mouse samples.Synonyms: 11beta-HSD2, Corticosteroid 11beta-Dehydrogenase Isozyme 2. Immunogen: Synthetic peptide from the N-terminal region of human 11beta-HSD2. MW: 44 kDa. Formulation: (Request formulation change), 500 µl of peptide affinity-purified polyclonal antibody. Storage Buffer: TBS, pH 7.4, with 50% glycerol, 0.1% BSA, and 0.02% sodium azide. Host: Rabbit. Applications: IHC, WB. UniProt Accession #: P80365. Origin: Animal/Rabbit.